StreetInsider.com News Articles

Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo

Thu, 28 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260528/26569367.html

Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo

Thu, 28 May 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260528/26569367.html

Aptevo Therapeutics names Mary Janatpour as chief scientific officer

Thu, 28 May 2026 08:05:08 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) appointed Mary J. Janatpour as Senior Vice President and Chief Scientific Officer, the clinical-stage biotechnology company announced.

Janatpour brings more than 25 years of oncology research and development experience across biotechnology and pharmaceutical organizations. She will lead Aptevo's research and preclinical development efforts and advance the company's pipeline of multispecific therapeutics based on its ADAPTIR and ADAPTIR-FLEX platform technologies.

The appointment comes as Aptevo focuses clinically on mipletamig while advancing a preclinical strategy that includes a radiopharmaceutical therapeutic collaboration with Niowave and an expanding multispecific oncology pipeline.

"Mary joins Aptevo at a pivotal moment as we continue to

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

Thu, 28 May 2026 08:05:00 -0400

Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy

SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™ platform technologies, today announced the appointment of Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer.

Dr. Janatpour brings more than 25 years of oncology research and development leadership across biotechnology and pharmaceutical organizations, with deep expertise spanning target discovery, translational science, and pipeline strategy.

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

Thu, 28 May 2026 08:05:00 -0400

Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy

Form 8-K Aptevo Therapeutics Inc. For: May 25

Wed, 27 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260527/26557776.html

Form 8-K Aptevo Therapeutics Inc. For: May 25

Wed, 27 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260527/26557776.html

Aptevo and Niowave form partnership for cancer drug development

Wed, 27 May 2026 08:05:49 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. announced a strategic collaboration to develop up to three radiopharmaceutical oncology programs. The 50/50 partnership combines Aptevo's multispecific antibody platforms with Niowave's radioisotope production capabilities.

Niowave made an equity investment in Aptevo at closing, acquiring an initial 7.9% ownership position. The investment structure includes warrants that could allow Niowave to increase its stake to 19.99% through future purchases at a premium to the initial price.

Under the agreement, Aptevo will contribute assets from its ADAPTIR and ADAPTIR-FLEX platforms, starting with targeting assets directed against Nectin-4, a protein expressed on cancer cell surfaces. Niowave will

Aptevo and Niowave form partnership for cancer drug development

Wed, 27 May 2026 08:05:49 -0400

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Wed, 27 May 2026 08:05:00 -0400

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology

SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, and Niowave, Inc., a leader in radioisotope production and supply with established partnerships across the radiopharmaceutical ecosystem, today announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs.

Niowave made an at-the-market equity investment in Aptevo at

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Wed, 27 May 2026 08:05:00 -0400

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs

Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology

Niowave made an at-the-market equity investment in Aptevo at

Form 10-Q Aptevo Therapeutics Inc. For: Mar 31

Wed, 13 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26486268.html

Form 10-Q Aptevo Therapeutics Inc. For: Mar 31

Wed, 13 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26486268.html

Form 8-K Aptevo Therapeutics Inc. For: May 13

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485885.html

Form 8-K Aptevo Therapeutics Inc. For: May 13

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485885.html

Aptevo names Jeff Lamothe CEO, reports AML trial progress

Wed, 13 May 2026 08:07:51 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) announced Jeff Lamothe has been appointed president and chief executive officer, while Marvin White transitioned to executive chair. The clinical-stage biotechnology company also provided updates on its RAINIER trial for acute myeloid leukemia treatment.

The company reported that its drug candidate mipletamig demonstrated an 87% clinical benefit rate and 81% remission rate in frontline AML patients when combined with venetoclax and azacitidine. The data, collected from 31 evaluable patients across RAINIER Cohort 5 and a previous dose expansion trial, showed 65% of patients achieved complete remission.

No cytokine release syndrome was observed in frontline patients, according to

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Wed, 13 May 2026 08:05:00 -0400

Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients

Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair

$60 million equity line of credit enhances financial flexibility and extends access to capital through achievement of key catalysts into 2029

SEATTLE, WA / ACCESS Newswire / May 13, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™platform technologies, today provided a business update.

"Aptevo is entering

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Wed, 13 May 2026 08:05:00 -0400

Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients
Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair
$60 million equity line of credit enhances financial flexibility and extends access to capital through achievement of key catalysts into 2029

SEATTLE, WA / ACCESS Newswire / May 13, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™platform technologies, today provided a business update.
"Aptevo is entering

Form 8-K Aptevo Therapeutics Inc. For: May 06

Wed, 06 May 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260506/26443735.html

Form 8-K Aptevo Therapeutics Inc. For: May 06

Wed, 06 May 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260506/26443735.html

Aptevo reports 87% clinical benefit rate in frontline AML trial

Wed, 06 May 2026 08:10:14 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) reported clinical results from its RAINIER Phase 1b trial evaluating mipletamig in combination with venetoclax and azacitidine for frontline acute myeloid leukemia treatment.

The company said 31 evaluable frontline AML patients demonstrated an 87% clinical benefit rate and 81% remission rate across data through Cohort 5 plus four patients from a previously completed dose expansion trial. The results include a 65% complete remission rate.

The trial compares to historical benchmark data from the Phase 3 VIALE-A trial, which reported a 66.4% composite complete remission rate and 37% complete remission rate for venetoclax plus azacitidine in similar patient

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D

Wed, 06 May 2026 08:05:00 -0400

Program Enters Final Stage of Dose Optimization
Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset

SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.
Across 31 evaluable frontline

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D

Wed, 06 May 2026 08:05:00 -0400

Program Enters Final Stage of Dose Optimization
Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset

SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.
Across 31 evaluable frontline

Form 10-K Aptevo Therapeutics Inc. For: Dec 31

Thu, 26 Mar 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260326/26224780.html

Form 10-K Aptevo Therapeutics Inc. For: Dec 31

Thu, 26 Mar 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260326/26224780.html